| Aug 28 |
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
|
| Aug 14 |
Pharvaris GAAP EPS of -€0.55
|
| Aug 14 |
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 16 |
Three Surprising Names That Could Be On Biogen's Buyout Shortlist
|
| Jul 16 |
Viridian, Pharvaris said to be among prime M&A targets for Biogen
|
| Jun 11 |
Pharvaris Announces Annual Meeting of Shareholders
|
| Jun 4 |
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
|
